Mordin Margaret, Parrish William, Masaquel Catherine, Bisson Brad, Copley-Merriman Catherine
Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA.
Department of Medical Affairs, DePuy Synthes, Raynham, MA, USA.
Clin Med Insights Arthritis Musculoskelet Disord. 2021 Nov 19;14:11795441211047284. doi: 10.1177/11795441211047284. eCollection 2021.
The economic impact of intra-articular hyaluronic acid (IAHA) for the treatment of knee pain associated with osteoarthritis (OA) has been evaluated in the United States, but not systematically summarized.
We reviewed the literature to determine the economic impact of IAHA for pain associated with knee OA in the United States.
A literature review was performed in PubMed (including MEDLINE and MEDLINE In-Process), Embase, the Cochrane Database of Systematic Reviews, and National Health Service Economic Evaluation Database and was limited to English language human studies published from January 2000 to October 2020.
The literature search identified 215 unique abstracts; of these, 47 were selected for full-text review and 21 studies met the inclusion criteria. Intra-articular hyaluronic acid injections delayed progression to total knee arthroplasty (TKA), and repeated courses of treatment successfully delayed TKA by more than 5 years. Intra-articular hyaluronic acid was found to reduce the use of pain medications overall and reduce the number of patients receiving opioid prescriptions by 6% ( < .001). Several studies showed that IAHA is more cost-effective in treating pain associated with knee OA compared with conventional care with nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids, and several authors concluded that IAHA should be the dominant treatment strategy.
Current studies suggest that IAHA may reduce the use of pain medications, such as NSAIDs and opioids, and impact time to TKA procedures, thus potentially decreasing overall treatment costs of knee OA over time. Furthermore, IAHA was determined to be cost-effective against NSAIDs, corticosteroids, analgesics, and conservative treatment. As the safety and efficacy of IAHA for knee OA have been well established, the findings from our literature review may be used to inform future economic evaluations.
在美国,已对关节内注射透明质酸(IAHA)治疗与骨关节炎(OA)相关的膝关节疼痛的经济影响进行了评估,但尚未进行系统总结。
我们回顾文献,以确定IAHA对美国膝关节OA相关疼痛的经济影响。
在PubMed(包括MEDLINE和MEDLINE在研数据库)、Embase、Cochrane系统评价数据库和英国国家卫生服务经济评价数据库中进行文献检索,仅限于2000年1月至2020年10月发表的英文人体研究。
文献检索共识别出215篇独特的摘要;其中47篇被选作全文审查,21项研究符合纳入标准。关节内注射透明质酸可延缓全膝关节置换术(TKA)的进展,重复疗程成功将TKA推迟了5年以上。发现关节内注射透明质酸总体上减少了止痛药物的使用,并使接受阿片类药物处方的患者数量减少了6%(P<0.001)。多项研究表明,与使用非甾体抗炎药(NSAIDs)、镇痛药和皮质类固醇的传统治疗相比,IAHA治疗膝关节OA相关疼痛更具成本效益,几位作者得出结论,IAHA应成为主要治疗策略。
目前的研究表明,IAHA可能会减少NSAIDs和阿片类药物等止痛药物的使用,并影响TKA手术的时间,从而有可能随着时间的推移降低膝关节OA的总体治疗成本。此外,已确定IAHA与NSAIDs、皮质类固醇、镇痛药和保守治疗相比具有成本效益。由于IAHA治疗膝关节OA的安全性和有效性已得到充分证实,我们文献综述的结果可用于为未来的经济评估提供参考。